Axonics® to Participate in September Investor Conferences
The Californer/10205659

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences:

Event: Wells Fargo Healthcare Conference
Date: Thursday, September 8, 2022
Time: 10:25 a.m. Eastern Time

Event: Morgan Stanley Healthcare Conference
Date: Monday, September 12, 2022
Time: 11:05 a.m. Eastern Time

Interested parties may access a live and archived webcast of each presentation by visiting the Axonics investor relations website.

More on The Californer

• AIXEBIT Exchange Launches Compliance Wall to Highlight Global Regulatory Alignment
• Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
• A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
• Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
• NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

More on The Californer

• Shore Scripts Announces Fall 2025 Short Film Fund Grant Recipients Al Benoit and Ericka Lavin
• California: Governor Newsom launches new initiatives to partner with tech policy experts and accelerate responsible AI in state government
• Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
• LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
• Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market

Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company's best-in-class urethral bulking hydrogel, Bulkamid^®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Contacts

Neil Bhalodkar
949-336-5293
ir@axonics.com

---

Show All News | Report Violation